Literature DB >> 10666259

JC virus enters human glial cells by clathrin-dependent receptor-mediated endocytosis.

M T Pho1, A Ashok, W J Atwood.   

Abstract

The human polyomavirus JC virus (JCV) is the etiologic agent of a fatal central nervous system (CNS) demyelinating disease known as progressive multifocal leukoencephalopathy (PML). PML occurs predominantly in immunosuppressed patients and has increased dramatically as a result of the AIDS pandemic. The major target cell of JCV infection and lytic replication in the CNS is the oligodendrocyte. The mechanisms by which JCV initiates and establishes infection of these glial cells are not understood. The initial interaction between JCV and glial cells involves virus binding to N-linked glycoproteins containing terminal alpha(2-6)-linked sialic acids. The subsequent steps of entry and targeting of the viral genome to the nucleus have not been described. In this report, we compare the kinetics and mechanisms of infectious entry of JCV into human glial cells with that of the related polyomavirus, simian virus 40 (SV40). We demonstrate that JCV, unlike SV40, enters glial cells by receptor-mediated clathrin-dependent endocytosis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10666259      PMCID: PMC111710          DOI: 10.1128/jvi.74.5.2288-2292.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Bound simian virus 40 translocates to caveolin-enriched membrane domains, and its entry is inhibited by drugs that selectively disrupt caveolae.

Authors:  H A Anderson; Y Chen; L C Norkin
Journal:  Mol Biol Cell       Date:  1996-11       Impact factor: 4.138

2.  Early events in polyoma virus infection: attachment, penetration, and nuclear entry.

Authors:  R L Mackay; R A Consigli
Journal:  J Virol       Date:  1976-08       Impact factor: 5.103

3.  Class I major histocompatibility proteins as cell surface receptors for simian virus 40.

Authors:  W J Atwood; L C Norkin
Journal:  J Virol       Date:  1989-10       Impact factor: 5.103

4.  The human polyomavirus, JCV, does not share receptor specificity with SV40 on human glial cells.

Authors:  C K Liu; A P Hope; W J Atwood
Journal:  J Neurovirol       Date:  1998-02       Impact factor: 2.643

5.  Interaction of the human polyomavirus, JCV, with human B-lymphocytes.

Authors:  W J Atwood; K Amemiya; R Traub; J Harms; E O Major
Journal:  Virology       Date:  1992-10       Impact factor: 3.616

6.  Early events in the infection of permissive cells with simian virus 40: adsorption, penetration, and uncoating.

Authors:  G Barbanti-Brodano; P Swetly; H Koprowski
Journal:  J Virol       Date:  1970-07       Impact factor: 5.103

Review 7.  Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain.

Authors:  E O Major; K Amemiya; C S Tornatore; S A Houff; J R Berger
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

8.  Class I major histocompatibility proteins are an essential component of the simian virus 40 receptor.

Authors:  W C Breau; W J Atwood; L C Norkin
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

9.  Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate.

Authors:  K G Rothberg; Y S Ying; B A Kamen; R G Anderson
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

10.  Caveolin forms a hetero-oligomeric protein complex that interacts with an apical GPI-linked protein: implications for the biogenesis of caveolae.

Authors:  M P Lisanti; Z L Tang; M Sargiacomo
Journal:  J Cell Biol       Date:  1993-11       Impact factor: 10.539

View more
  117 in total

Review 1.  A classification scheme for human polyomavirus JCV variants based on the nucleotide sequence of the noncoding regulatory region.

Authors:  P N Jensen; E O Major
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

2.  Caveolae are involved in the trafficking of mouse polyomavirus virions and artificial VP1 pseudocapsids toward cell nuclei.

Authors:  Z Richterová; D Liebl; M Horák; Z Palková; J Stokrová; P Hozák; J Korb; J Forstová
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 3.  Challenges for clinical trials to treat progressive multifocal leukoencephalopathy.

Authors:  David B Clifford
Journal:  J Neurovirol       Date:  2003       Impact factor: 2.643

Review 4.  Progressive multifocal leukoencephalopathy: clinical and molecular aspects.

Authors:  Eleonora Tavazzi; Martyn K White; Kamel Khalili
Journal:  Rev Med Virol       Date:  2011-09-21       Impact factor: 6.989

Review 5.  BK polyomavirus: emerging pathogen.

Authors:  Shauna M Bennett; Nicole M Broekema; Michael J Imperiale
Journal:  Microbes Infect       Date:  2012-02-24       Impact factor: 2.700

6.  Endocytosis of hepatitis C virus non-enveloped capsid-like particles induces MAPK-ERK1/2 signaling events.

Authors:  Konstantina Katsarou; Alexandros Alpha Lavdas; Panagiota Tsitoura; Elisavet Serti; Panagiotis Markoulatos; Penelope Mavromara; Urania Georgopoulou
Journal:  Cell Mol Life Sci       Date:  2010-04-01       Impact factor: 9.261

Review 7.  Cell Walls and the Convergent Evolution of the Viral Envelope.

Authors:  Jan P Buchmann; Edward C Holmes
Journal:  Microbiol Mol Biol Rev       Date:  2015-12       Impact factor: 11.056

8.  Invasion of host cells by JC virus identifies a novel role for caveolae in endosomal sorting of noncaveolar ligands.

Authors:  W Querbes; B A O'Hara; G Williams; W J Atwood
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

9.  Influenza virus can enter and infect cells in the absence of clathrin-mediated endocytosis.

Authors:  Sara B Sieczkarski; Gary R Whittaker
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  High-throughput cell-based screen for chemicals that inhibit infection by simian virus 40 and human polyomaviruses.

Authors:  Edward C Goodwin; Walter J Atwood; Daniel DiMaio
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.